Apollo Technology Capital Corporation, a significant shareholder of MediPharm Labs Corp., has issued voting recommendations ahead of the company's 2025 Annual and Special Meeting of Shareholders scheduled for June 16. Apollo Capital, owning approximately 3.0% of MediPharm's common stock, urges shareholders to disregard MediPharm's green proxy card and instead vote for the gold proxy card in support of Apollo Capital's six director nominees. These nominees-John Fowler, Alan D. Lewis, David Lontini, Demetrios Mallios, Regan McGee, and Scott Walters-are presented as highly qualified candidates capable of addressing issues such as strategic failures and excessive executive compensation at MediPharm. Apollo Capital has launched a campaign website, CureMediPharm.com, to outline their five-pillar plan aimed at restoring value and accountability to the company.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。